# reload+after+2024-01-20 13:43:24.518533
address1§30 Technology Drive
city§Warren
state§NJ
zip§07059
country§United States
phone§908 941 1900
website§https://www.aquestive.com
industry§Drug Manufacturers—Specialty & Generic
sector§Healthcare
longBusinessSummary§Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and AQST-109, an orally delivered epinephrine product candidate for the emergency treatment of allergic reactions, including anaphylaxis. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.
fullTimeEmployees§130
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Daniel  Barber', 'age': 47, 'title': 'CEO, President & Director', 'yearBorn': 1976, 'fiscalYear': 2022, 'totalPay': 925345, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Alexander Mark Schobel', 'age': 64, 'title': 'Chief Innovation & Technology Officer', 'yearBorn': 1959, 'fiscalYear': 2022, 'totalPay': 672689, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Lori J. Braender BSBA, Esq., J.D.', 'age': 67, 'title': 'Senior VP, General Counsel, Chief Compliance Officer & Corporate Secretary', 'yearBorn': 1956, 'fiscalYear': 2022, 'totalPay': 678757, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. A. Ernest Toth Jr.', 'age': 64, 'title': 'Chief Financial Officer', 'yearBorn': 1959, 'fiscalYear': 2022, 'totalPay': 679896, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Cassie  Jung', 'age': 44, 'title': 'Senior Vice President of Operations', 'yearBorn': 1979, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Peter E. Boyd', 'age': 57, 'title': 'Senior Vice President of IT, HR & Communications', 'yearBorn': 1966, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Kenneth W. Marshall', 'age': 64, 'title': 'Chief Commercial Officer', 'yearBorn': 1959, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Gary H. Slatko M.D., MBA', 'age': 66, 'title': 'Chief Medical Officer', 'yearBorn': 1957, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Stephen  Wargacki', 'age': 45, 'title': 'Senior VP of Research & Development', 'yearBorn': 1978, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Carl N. Kraus M.D.', 'age': 53, 'title': 'Chief Medical Officer', 'yearBorn': 1970, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§9
boardRisk§6
compensationRisk§7
shareHolderRightsRisk§8
overallRisk§7
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§2.673
priceToSalesTrailing12Months§3.2509098
currency§USD
dateShortInterest§1702598400
forwardEps§-0.25
exchange§NGM
quoteType§EQUITY
shortName§Aquestive Therapeutics, Inc.
longName§Aquestive Therapeutics, Inc.
firstTradeDateEpochUtc§1532525400
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§22956725-87cb-39ad-9e8b-1bc1480b8337
gmtOffSetMilliseconds§-18000000
targetHighPrice§10.0
targetLowPrice§3.0
targetMeanPrice§6.33
targetMedianPrice§6.5
recommendationMean§1.7
recommendationKey§buy
numberOfAnalystOpinions§6
quickRatio§1.391
grossMargins§0.55353
ebitdaMargins§-0.42576998
trailingPegRatio§None
